Pediatric Cancer Metabolism Laboratory, Children's Research Center,
University of Zurich, 8032 Zurich, Suisse
hôte : Alexandre DAVID (IRCM)
Group Leader, Tumor Immunotherapy and Microenvironment
Luxembourg Institute of Health, Department of Cancer Research
contact : Andrei Turtoi (IRCM)
CR Inserm,
Laboratoire Restore, Equipe Metabolink
UMR 1301 Inserm 5070, CNRS, Université Paul Sabatier (Toulouse)
Aging, is a physiological process often characterized by declining function over time and the primary risk factor for many age-related diseases, impacting health and survival. The World Health Organization (WHO) identifies five key domains to track health during aging, which can reveal frailty as a sign of unhealthy aging and precursor of dependency. Intrinsic capacity (IC) is a metric encompassing these five domains, reflecting the overall physical and mental abilities of an individual, and is now recognized as measurable and predictive of key attributes that support healthy aging. While certain blood biomarkers are linked to frailty syndrome in old individuals, there is a need for one or a set of biomarkers that can predict the risk of frailty in younger individuals. This would allow for the implementation of suitable preventive or intervention strategies to reduce the likelihood or severity of frailty. While IC is associated with comorbidities and frailty, no studies have been conducted to determine whether biomarkers of aging are associated with IC at all ages. The key challenge is to identify correlations between molecular markers and IC, which could improve our understanding of the mechanisms driving functional decline and provide valuable targets for early risk detection and intervention. Despite extensive research, a gap persists in linking systemic and cellular changes to broader aging phenotypes like IC and frailty. In our multiscale study, we aimed to identify functional health markers using samples from the INSPIRE human translational cohort (INSPIRE-T cohort). This cohort included 1000 participants for the plasma study and 133 for the skin fibroblast study, ranging in age from 20 to 96 years, and covering a spectrum of frailty levels (robust, pre-frail, frail) and IC scores. At the systemic scale, plasma samples allowed us to map energy metabolism associated with functional decline and IC, while at the cellular scale, dermal fibroblasts from skin biopsies helped identify health markers, molecular targets, and reveal mechanisms related to aging and IC.??
hôte : Pierre-François Roux (équipe Le Cam), IRCM